Phantom Neuro's Insights on Human-Machine Integration at BioFuture
Phantom Neuro's Insights on Human-Machine Integration at BioFuture
Austin-headquartered neurotech innovator Phantom Neuro is making waves in the cutting-edge world of human-machine interfaces. Dr. Connor Glass, the company's visionary CEO and founder, will be sharing his insights during a keynote presentation at the prestigious BioFuture™ 2025 conference. This year, the event will take place in New York City, spotlighting forward-thinking discussions amongst key leaders in the biotech and healthcare industries.
What to Expect at BioFuture™ 2025
This year’s BioFuture conference promises to be a hub of creativity and collaboration. Dr. Connor Glass will be featured prominently, participating in a panel titled "Rewiring Minds: Breakthroughs in Brain & CNS Health". This discussion will delve into how recent advancements in technology and policy are reshaping healthcare delivery and innovation pathways. Panelists will include top experts from various sectors, highlighting the interconnected nature of health technologies and their transformative potential.
Details About the Spotlight Panel
The Spotlight Panel featuring Dr. Glass is scheduled for **Monday, October 13**, from 11:00 AM to 12:00 PM, located on the 12th floor of Cure at 345 Park Ave S., New York, NY 10010. Ginger Johnson, Senior Vice President at Lumanity, will moderate these discussions, ensuring a dynamic exchange of ideas and insights.
Key Participants Shaping the Future
Alongside Dr. Glass, several notable industry leaders will participate in this crucial conversation, including:
- Adam Rogers, CEO of NervGen Pharma
- Arun Swaminathan, CEO of Coya Therapeutics, Inc.
- Brent Vaughan, CEO and Founder of Eratos Therapeutics
- Beth Hoffman, CEO of Origami Therapeutics, Inc.
This esteemed group will address a myriad of subjects relating to innovative advancements and the strategic directions that their respective organizations are pursuing.
Recent Achievements of Phantom Neuro
Phantom Neuro has experienced remarkable growth in a short timeframe, underlined by significant milestones such as receiving prestigious FDA Breakthrough Device and TAP Designations. These accolades not only validate the company’s technology but also help to solidify its position as a leader in the neurotech space.
More recently, the company has announced a major funding round, welcomed a new strategic partner—Ottobock, a renowned name in medical robotics—and made headlines with its pioneering research. Phantom Neuro’s published peer-reviewed white paper showcases breakthroughs from the patented Phantom X platform, illustrating effective user control of prosthetic devices. This highlights the company’s commitment to enhancing the user experience and real-world applicability.
About Phantom Neuro
Phantom Neuro stands at the forefront of neurotechnology, innovating minimally invasive interfaces designed for intuitive control of prosthetic limbs and robotic systems. This technology is the result of groundbreaking research initially conducted at the esteemed Johns Hopkins University School of Medicine. With backing from key investors—such as Ottobock and Blackrock Neurotech—alongside support from a distinguished advisory board comprising experts from various reputable institutions, Phantom Neuro continues to evolve as a beacon of innovation.
Frequently Asked Questions
What is the main focus of Phantom Neuro?
Phantom Neuro specializes in developing innovative human-machine interfaces that allow for intuitive control of prosthetic limbs and robotic exoskeletons, enhancing quality of life.
Who will be participating in the Spotlight Panel at BioFuture?
The panel features leading industry figures including Dr. Connor Glass, Adam Rogers, Arun Swaminathan, Brent Vaughan, and Beth Hoffman.
Where and when will the Spotlight Panel take place?
The panel will occur on **Monday, October 13**, from 11:00 AM to 12:00 PM on the 12th floor of Cure, located at 345 Park Ave S., New York, NY 10010.
What recent achievements has Phantom Neuro accomplished?
Phantom Neuro has received FDA Breakthrough Device and TAP Designations and published significant research findings, further establishing its role in the neurotech landscape.
How does Phantom Neuro collaborate with other organizations?
Phantom Neuro collaborates with various partners like Ottobock to enhance its technology and expand its reach into medical and industrial robotics, ensuring continuous growth and innovation.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
